Men with aggressive prostate cancer that has stopped responding to conventional treatment could potentially benefit from a new class of cancer drug designed to overcome drug resistance, a new study suggests.
Dr Chris Parker, Chair of the NCRI's Prostate Cancer Clinical Studies Group, said: «There's a need to develop better tests to identify and monitor
men with aggressive prostate cancer.
The researchers, led by Dr Alexandre R. Zlotta, of the Lunenfeld - Tanenbaum Research Institute (Toronto, Canada) and Paul Boutros (Ontario Institute for Cancer Research) intensively searched for small single - point inherited mutations in the whole Kallikrein region, in a large group of 1858 men
with aggressive prostate cancer (defined as having a Gleason score above 8).
I was diagnosed — through a number of tests beyond PSA levels —
with an aggressive prostate cancer, which has been successfully treated by surgery.
In 2002, at age 48, I was diagnosed
with aggressive prostate cancer.